Newly emerging data from the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial: an investigator’s perspective.
Congress Presentation
About the speaker
Doctor Paul Wayne Armstrong
6 more presentations in this session
Welcome and introduction - Clinical considerations for cardiologists: exploring the evidence for primary and secondary prevention in type 2 diabetes.
Speaker: Professor G. De Ferrari (Turin, IT) Professor L. Leiter (Toronto, CA)
Coprevalence of comorbidities and their role in the choices of treatment for the diabetic patient with cardiovascular disease.
Speaker: Professor N. Marx (Aachen, DE)
Diabetes cardiovascular safety trials: an endocrinologist’s interpretation of emergent data.
Speaker: Professor L. Leiter (Toronto, CA)
Closing the gap: the EUROASPIRE study (European Action on Secondary Prevention by Intervention to Reduce Events) and what it can tell us for the treatment of diabetes patients.
Speaker: Professor L. Ryden (Stockholm, SE)
Q&A - Clinical considerations for cardiologists: exploring the evidence for primary and secondary prevention in type 2 diabetes.
Speaker: Professor N. Marx (Aachen, DE) Doctor P. Armstrong (Edmonton, CA) Professor L. Ryden (Stockholm, SE) Professor L. Leiter (Toronto, CA)
Access the full session
Clinical considerations for cardiologists: exploring the evidence for primary and secondary prevention in type 2 diabetes
About the event
ESC 365 is supported by
